Covis Pharma Initiates Phase 3 Clinical Trial of Alvesco Inhaler for COVID-19

Covis Pharma has begun a phase 3 trial of its approved asthma drug Alvesco (ciclesonide) in non-hospitalized COVID-19 patients ages 12 years and older.

The drugmaker will test the inhaled treatment in 400 patients at multiple sites across the U.S. The patients will receive Alvesco with the standard supportive care or a placebo with standard supportive care.

Early results of the trial are expected by late August or early September.